Truist Securities Upgrades Janux Therapeutics to Buy

Truist Securities has upgraded its rating on Janux Therapeutics, Inc. (NasdaqGM: JANX) to Buy, setting a price target of $26. This upgrade was announced on June 25, 2026, by analyst Supawat Thongthip, marking a positive outlook for the biotechnology company.

Other Institutional Activity in Janux Therapeutics

RA Capital Management, L.P. held steady with 11,189,693 shares worth about $155.5 million. BlackRock, Inc. increased its stake by 1,353,033 shares, bringing its total to 5,433,233 shares valued at approximately $75.5 million, a 33.2% rise. Meanwhile, Janus Henderson Group PLC reduced its holdings by 1,154,044 shares, leaving it with 4,196,409 shares worth about $58.3 million, a 21.6% decrease. Prosight Management, LP expanded its position by 1,157,477 shares to 3,550,000 shares, valued at about $49.3 million, a 48.4% increase. FMR LLC cut its stake by 976,660 shares, ending with 2,535,724 shares valued at $35.2 million, a 27.8% decrease.

Janux Therapeutics, Inc. Stock Down 17.1%

Shares of Janux Therapeutics traded near $14.64 on Thursday. The company has a market cap of approximately $874.5 million. Although it isn't profitable, its forward P/E ratio is -5.17, and it has a beta of 2.52, indicating higher volatility. The stock's 52-week range is between $12.12 and $35.34, with a 50-day moving average of $14.41 and a 200-day moving average of $18.05.

Recent Earnings

For its most recent quarter, Janux Therapeutics reported revenue of $13.73 million. However, the company is not yet profitable, with a negative return on equity of -11.7%. The next earnings release is expected on August 6, 2026.

Insider Buying and Selling at Janux Therapeutics, Inc.

On June 11, 2026, several insiders, including Winston Kung, Ronald Barrett, and Natasha Hernday, purchased shares. Each insider acquired 5,500 shares, while RA Capital Management and Vickie Capps bought 15,500 shares each.

Analysts Set New Price Targets

On June 25, 2026, Truist Securities assumed coverage with a Buy rating and a $26 price target. Piper Sandler and Wedbush both maintained Buy ratings on May 8, 2026, with targets of $26 and $36, respectively. Guggenheim also maintained a Buy rating with a $58 target. In contrast, Barclays downgraded the stock to Sell with a $14 target on April 20, 2026.

About Janux Therapeutics

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in San Diego, California. It focuses on developing innovative immunotherapies using its proprietary TRACTr, TRACIr, and ARM platforms. The company targets various cancers, with clinical candidates like JANX007 and JANX008 in Phase 1 trials. Led by CEO Dr. David Alan Campbell, the company engages in strategic collaborations with major pharmaceutical companies like Merck and Bristol Myers Squibb.

Bottom Line

Truist Securities' upgrade to a Buy rating suggests confidence in Janux Therapeutics' potential, especially given its innovative cancer therapies. While the stock's past performance has been volatile, ongoing insider buying and strategic partnerships might attract investor interest. As always, it's important to remember that analyst ratings are based on past data and may not reflect future performance.